Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Juliann Chmielecki"'
Autor:
Jong Seok Lee, Jonathan W. Goldman, Jin Seok Ahn, Myung-Ju Ahn, Tae Min Kim, Byoung Chul Cho, Juliann Chmielecki, Dong Wan Kim, Karthick Vishwanathan, Ronald B. Natale, Ariadna Mendoza-Naranjo, Andrew P. Brown, Barbara Collins, Dae H. Lee, Sang We Kim, James Chih-Hsin Yang
Publikováno v:
Journal of Clinical Oncology
PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non–sm
Autor:
Paul D. Smith, Ursula Grazini, Tereza Vaclova, J. Carl Barrett, Elza C. de Bruin, Kenneth S. Thress, Aleksandra Markovets, Ryan J. Hartmaier, Lewis S. C. Ward, Daniel O'Neill, Julian Downward, Juliann Chmielecki, X. Huang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature Communications
Nature Communications
Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Here we show that the size of the EGFR T790M-positive clone impa
Autor:
Volkan Adsay, Long Cao, Gokce Askan, Ruth Aryeequaye, Ahmet Zehir, Serdar Balci, Juliann Chmielecki, Mamta Rao, Ryma Benayed, David S. Klimstra, Olca Basturk, Irina Linkov, Philip J. Stephens, Lu Wang, Jeffrey S. Ross, Sumit Middha, Jiajing Wang
Publikováno v:
Modern Pathology. 31:132-140
Approximately 1-2% of pancreatic neoplasms are acinar cell carcinomas. Recently, BRAF gene rearrangements were identified in over 20% of acinar-type neoplasms, which included both pure acinar cell carcinomas and mixed carcinomas with acinar different
Autor:
Juliann Chmielecki, Timothy A. Chan, Kathryn Beal, Philip H. Gutin, Elena Pentsova, Viviane Tabar, Michael E. Goldberg, Cameron Brennan, Malbora Manne, David B. Solit, Bob T. Li, Thomas Kaley, Adrienne Boire, Igor T. Gavrilovic, Shahiba Ogilvie, Michael F. Berger, Jacqueline B. Stone, Mariza Daras, Robert J. Young, Anna F. Piotrowski, Eli L. Diamond, David M. Hyman, Angela G. Arnold, Natalie DiStefano, Shweta S. Chavan, Antonio Omuro, Marc K. Rosenblum, Maryam Pourmaleki, Alexandra Miller, Ingo K. Mellinghoff, Zsofia K. Stadler, Philip Jonsson, Christian Grommes, Lisa M. DeAngelis, Andrew T. McKeown, Andrew L. Lin, Allison Hyde, Barry S. Taylor, Diana Mandelker, Marc Ladanyi, Ahmet Zehir, T. Jonathan Yang, Craig Nolan
Purpose: The genomic landscape of gliomas has been characterized and now contributes to disease classification, yet the relationship between molecular profile and disease progression and treatment response remain poorly understood. Experimental Desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b774e55d848d4f7aea3a11cce8af25
https://europepmc.org/articles/PMC6753053/
https://europepmc.org/articles/PMC6753053/
Autor:
Siraj M. Ali, Juliann Chmielecki, Philip J. Stephens, Doron Lipson, Sumanta K. Pal, Vincent A. Miller, Jamie Buell, Roman Yelensky, Edward Dow, Garrett M. Frampton, Julia A. Elvin, Mark Bailey, Rachel Squillace, Kai Wang, Norma Alonzo Palma, Peter M. Howley, Jeffrey S. Ross, Deborah Morosini, Jie He, Eric M. Sanford
Publikováno v:
The Oncologist. 21:33-39
Background Advanced penile squamous cell carcinoma (PSCC) is associated with poor survival due to the aggressiveness of the disease and lack of effective systemic therapies. Comprehensive genomic profiling (CGP) was performed to identify clinically r
Autor:
Jeffrey S. Ross, Kai Wang, Juliann Chmielecki, Laurie Gay, Adrienne Johnson, Jacob Chudnovsky, Roman Yelensky, Doron Lipson, Siraj M Ali, Julia A. Elvin, Jo‐Anne Vergilio, Steven Roels, Vincent A Miller, Brooke N. Nakamura, Adam Gray, Michael K Wong, Philip J Stephens
Publikováno v:
International Journal of Cancer
Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profi
Autor:
Lynette M. Sholl, Malak Abedalthagafi, Ziming Du, Josh Francis, Lars Geffers, Parker H. Merrill, Juliann Chmielecki, Sandro Santagata, Brian M. Alexander, Ayal A. Aizer, Ryan Brewster
Publikováno v:
Neuro-Oncology
Background Tumor cells recapitulate cell-lineage transcriptional programs that are characteristic of normal tissues from which they arise. It is unclear why such lineage programs are fatefully maintained in tumors and if they contribute to cell proli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb68d3635c4d2230436158ba9ff6482e
https://europepmc.org/articles/PMC6120365/
https://europepmc.org/articles/PMC6120365/
Autor:
Riley Ennis, Franklin W. Huang, Uri Tabori, Mark Kennedy, Jared White, Brittany Campbell, Caitlin F. Connelly, Siraj M. Ali, Alexa B. Schrock, Steven Roels, James Sun, David Fabrizio, Jeffrey S. Ross, Phillip J. Stephens, Daniel S. Lieber, Yuting He, Vincent A. Miller, Juliann Chmielecki, Levi A. Garraway, Garrett M. Frampton, Zachary R. Chalmers, Adam Shlien, G. Otto
Publikováno v:
Genome Medicine
Genome Medicine, Vol 9, Iss 1, Pp 1-14 (2017)
Genome Medicine, Vol 9, Iss 1, Pp 1-14 (2017)
Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 exp
Autor:
Juliann Chmielecki, Ryan J. Hartmaier, Vincent A. Miller, Jeffrey S. Ross, Phil Stephens, Rachel L. Erlich, Christine A. Parachoniak, Bernadette Gaffney, John Keech, Deborah Morosini, Andrew Rankin, Dan Spritz
Publikováno v:
Cold Spring Harbor Molecular Case Studies
Metastatic triple-negative breast cancer comprises 12%–17% of breast cancers and carries a poor prognosis relative to other breast cancer subtypes. Treatment options in this disease are largely limited to systemic chemotherapy. A majority of clinic
Autor:
Kai Wang, Juliann Chmielecki, Deborah Morosini, Gary A. Palmer, Doron Lipson, Siraj M. Ali, Christine E. Sheehan, V.A. Miller, J.A. Elvin, L Foulke, Phillip J. Stephens, J.S. Ross, Osama El-Kadi, G. Otto, Ashley J Tarasen, Roman Yelensky
Publikováno v:
Journal of Clinical Pathology
AimsSmall cell lung cancer (SCLC) carries a poor prognosis, and the systemic therapies currently used as treatments are only modestly effective, as demonstrated by a low 5-year survival at only ∼5%. In this retrospective collected from March 2013 t